RELMADA THERAPEUTICS, INC. Investment Income, Interest
RELMADA THERAPEUTICS, INC. (RLMD) reported Investment Income, Interest of $2.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-06-30 was $2.30M, a 615.92% increase year-over-year.
- RELMADA THERAPEUTICS, INC. investment income, interest for the quarter ending 2026-03-31 was $959.76K, a 117.99% increase year-over-year.
- RELMADA THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-12-31 was $387.23K, a 40.85% decline year-over-year.
- RELMADA THERAPEUTICS, INC. investment income, interest for the quarter ending 2025-09-30 was $247.01K, a 71.16% decline year-over-year.
- RELMADA THERAPEUTICS, INC. investment income, interest for fiscal 2025 was $1.40M, a 60.45% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. investment income, interest for fiscal 2024 was $3.53M, a 31.48% decline from fiscal 2023.
- RELMADA THERAPEUTICS, INC. investment income, interest for fiscal 2023 was $5.15M.
- RELMADA THERAPEUTICS, INC. investment income, interest for fiscal 2015 was $10.88K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month | Investment Income, Interest 115 month | Investment Income, Interest 118 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.30M 10-Q · filed 2026-08-06 | $3.26M 10-Q · filed 2026-08-06 | $3.65M derived: sum of 3 quarters · filed 2026-08-06 | $3.90M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $959.76K 10-Q · filed 2026-05-12 | $1.35M derived: sum of 2 quarters · filed 2026-05-12 | $1.59M derived: sum of 3 quarters · filed 2026-05-12 | $1.92M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $387.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $634.24K derived: sum of 2 quarters · filed 2026-03-19 | $955.70K derived: sum of 3 quarters · filed 2026-08-06 | $1.40M 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $247.01K 10-Q · filed 2025-11-13 | $568.47K derived: sum of 2 quarters · filed 2026-08-06 | $1.01M 10-Q · filed 2025-11-13 | $1.66M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $321.46K 10-Q · filed 2026-08-06 | $761.75K 10-Q · filed 2026-08-06 | $1.42M derived: sum of 3 quarters · filed 2026-08-06 | $2.27M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $440.29K 10-Q · filed 2026-05-12 | $1.09M derived: sum of 2 quarters · filed 2026-05-12 | $1.95M derived: sum of 3 quarters · filed 2026-05-12 | $2.91M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $654.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.51M derived: sum of 2 quarters · filed 2026-03-19 | $2.47M derived: sum of 3 quarters · filed 2026-03-19 | $3.53M 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $856.48K 10-Q · filed 2025-11-13 | $1.82M derived: sum of 2 quarters · filed 2025-11-13 | $2.88M 10-Q · filed 2025-11-13 | $4.13M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $963.01K 10-Q · filed 2025-08-07 | $2.02M 10-Q · filed 2025-08-07 | $3.28M derived: sum of 3 quarters · filed 2025-08-07 | $4.60M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $1.06M 10-Q · filed 2025-05-12 | $2.32M derived: sum of 2 quarters · filed 2025-05-12 | $3.64M derived: sum of 3 quarters · filed 2025-05-12 | $5.00M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.58M derived: sum of 2 quarters · filed 2025-03-27 | $3.94M derived: sum of 3 quarters · filed 2025-03-27 | $5.15M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $1.32M 10-Q · filed 2024-11-07 | $2.68M derived: sum of 2 quarters · filed 2024-11-07 | $3.89M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $1.36M 10-Q · filed 2024-08-07 | $2.57M 10-Q · filed 2024-08-07 | ||||
| 2023-03-31 | $1.21M 10-Q · filed 2024-05-08 | |||||
| 2015-12-31 | $843.00 10-Q · filed 2016-02-05 | $1.89K 10-Q · filed 2016-02-05 | $3.12K derived: sum of 3 quarters · filed 2016-02-05 | $5.55K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2015-09-30 | $1.04K 10-Q · filed 2015-11-06 | $2.28K derived: sum of 2 quarters · filed 2015-11-06 | $4.71K derived: sum of 3 quarters · filed 2015-11-06 | $9.81K derived: sum of 4 quarters · filed 2016-02-05 | ||
| 2015-06-30 | $1.23K derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-11 | $3.66K derived: sum of 2 quarters · filed 2015-09-11 | $8.77K derived: sum of 3 quarters · filed 2016-02-05 | $10.88K 10-K · filed 2015-09-11 | ||
| 2015-03-31 | $2.43K 10-Q · filed 2015-05-15 | $7.53K derived: sum of 2 quarters · filed 2016-02-05 | $9.65K 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | $5.11K 10-Q · filed 2016-02-05 | $7.22K 10-Q · filed 2016-02-05 | ||||
| 2014-09-30 | $2.12K 10-Q · filed 2015-11-06 | |||||
| 2014-06-30 | $1.41K 10-K · filed 2015-09-11 | |||||
| 2014-03-31 | $69.45K 8-K · filed 2014-05-27 | |||||
| 2013-12-31 | $69.45K 8-K · filed 2014-05-27 | |||||
| 2012-12-31 | $12.75K 10-KT · filed 2014-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |